NO2700405T3 - - Google Patents
Info
- Publication number
- NO2700405T3 NO2700405T3 NO13168599A NO13168599A NO2700405T3 NO 2700405 T3 NO2700405 T3 NO 2700405T3 NO 13168599 A NO13168599 A NO 13168599A NO 13168599 A NO13168599 A NO 13168599A NO 2700405 T3 NO2700405 T3 NO 2700405T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2008/000358 WO2009144755A1 (en) | 2008-05-29 | 2008-05-29 | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
| EP08789969.6A EP2293804B1 (de) | 2008-05-29 | 2008-05-29 | Herpes simplex virus (hsv) mit modifiziertem tropismus, seine verwendungen und herstellungsverfahren |
| EP13168599.2A EP2700405B1 (de) | 2008-05-29 | 2008-05-29 | Herpes-Simplex-Virus (HSV) mit verändertem Tropismus, Verwendungen und Verfahren zur Herstellung davon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2700405T3 true NO2700405T3 (de) | 2018-09-01 |
Family
ID=40032777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO13168599A NO2700405T3 (de) | 2008-05-29 | 2008-05-29 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9157071B2 (de) |
| EP (2) | EP2700405B1 (de) |
| JP (1) | JP5683455B2 (de) |
| AU (1) | AU2008357065B2 (de) |
| DK (2) | DK2293804T3 (de) |
| ES (2) | ES2425489T3 (de) |
| HU (1) | HUE037311T2 (de) |
| NO (1) | NO2700405T3 (de) |
| PL (2) | PL2293804T3 (de) |
| PT (2) | PT2293804E (de) |
| WO (1) | WO2009144755A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
| BR112016009465A8 (pt) | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| WO2020142677A1 (en) * | 2019-01-03 | 2020-07-09 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| EP3256570B1 (de) | 2015-02-11 | 2021-03-31 | Alma Mater Studiorum -Universita' di Bologna | Retargetiertes herpesvirus mit einer glykoprotein h-fusion |
| KR20180136435A (ko) | 2016-01-27 | 2018-12-24 | 온코루스, 인크. | 종양 살상형 바이러스 벡터 및 그의 용도 |
| KR20190015544A (ko) * | 2016-06-09 | 2019-02-13 | 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 | 변형된 당단백질 d를 갖는 헤르페스 바이러스 |
| WO2017211945A1 (en) | 2016-06-09 | 2017-12-14 | Alma Mater Studiorum Universita Di Bologna | Herpesvirus with modified glycoprotein h for propagation in a cell |
| EP3469070B1 (de) | 2016-06-09 | 2021-08-04 | Alma Mater Studiorum - Università di Bologna | Herpesvirus mit modifiziertem glykoprotein b |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| WO2019044925A1 (ja) * | 2017-08-30 | 2019-03-07 | Ｋｍバイオロジクス株式会社 | 改変型ＨＳＶ ｇＤタンパク質及びこれを含むワクチン |
| EP3731850A4 (de) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | Onkolytische virale verabreichung von therapeutischen polypeptiden |
| CA3103374A1 (en) * | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| EP3887529A4 (de) * | 2018-11-28 | 2022-08-31 | The Brigham & Women's Hospital, Inc. | Neue generation regulierbarer fusogener onkolytischer viren des herpes-simplex-virentyps 1 und verfahren zur verwendung |
| WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| KR102311895B1 (ko) * | 2020-06-12 | 2021-10-14 | 주식회사 젠셀메드 | 재표적화를 위한 변형된 당단백질 gH를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도 |
| CN112501137B (zh) * | 2020-11-11 | 2023-10-20 | 深圳先进技术研究院 | 一种神经环路标记系统 |
| EP4334439A1 (de) * | 2021-05-05 | 2024-03-13 | Janssen Biotech, Inc. | Universelles neutargeting von onkolytischem hsv |
| CN113969287B (zh) * | 2021-10-22 | 2024-05-28 | 中国科学院深圳先进技术研究院 | 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| CA2279547A1 (en) | 1997-01-31 | 1998-08-06 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| US6080399A (en) | 1998-04-23 | 2000-06-27 | Arch Development Corporation | Vaccine adjuvants for immunotherapy of melanoma |
| US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| EP1390069A1 (de) | 2001-05-30 | 2004-02-25 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma-antikörper-fusionsproteine zur behandlung von krebs |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| US20040115688A1 (en) | 2002-04-19 | 2004-06-17 | Cheung Irene Y. | Detection of gd2 synthase mrna and uses thereof |
| US20070243170A1 (en) * | 2002-10-07 | 2007-10-18 | The University Of Chicago | Targeting of Herpes Simplex Virus to Specific Receptors |
| EP1549339B1 (de) | 2002-10-07 | 2019-06-05 | University Of Chicago | Targeting von herpes simplex virus an spezifische rezeptoren |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| JP5219819B2 (ja) | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| US20080038224A1 (en) | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
| EP2423307A1 (de) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modifizierte Gerinnungsfaktor-IV-Polypeptide und deren Verwendung bei der Behandlung |
| GB0714578D0 (en) * | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
-
2008
- 2008-05-29 NO NO13168599A patent/NO2700405T3/no unknown
- 2008-05-29 ES ES08789969T patent/ES2425489T3/es active Active
- 2008-05-29 ES ES13168599.2T patent/ES2667622T3/es active Active
- 2008-05-29 AU AU2008357065A patent/AU2008357065B2/en not_active Ceased
- 2008-05-29 HU HUE13168599A patent/HUE037311T2/hu unknown
- 2008-05-29 PL PL08789969T patent/PL2293804T3/pl unknown
- 2008-05-29 PT PT87899696T patent/PT2293804E/pt unknown
- 2008-05-29 PT PT131685992T patent/PT2700405T/pt unknown
- 2008-05-29 WO PCT/IT2008/000358 patent/WO2009144755A1/en not_active Ceased
- 2008-05-29 EP EP13168599.2A patent/EP2700405B1/de not_active Not-in-force
- 2008-05-29 DK DK08789969.6T patent/DK2293804T3/da active
- 2008-05-29 PL PL13168599T patent/PL2700405T3/pl unknown
- 2008-05-29 EP EP08789969.6A patent/EP2293804B1/de active Active
- 2008-05-29 JP JP2011511172A patent/JP5683455B2/ja active Active
- 2008-05-29 DK DK13168599.2T patent/DK2700405T3/en active
-
2010
- 2010-11-24 US US12/953,528 patent/US9157071B2/en active Active
-
2015
- 2015-09-24 US US14/864,098 patent/US9744199B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2700405A1 (de) | 2014-02-26 |
| US9744199B2 (en) | 2017-08-29 |
| US20110318268A1 (en) | 2011-12-29 |
| AU2008357065A1 (en) | 2009-12-03 |
| WO2009144755A1 (en) | 2009-12-03 |
| JP2011522532A (ja) | 2011-08-04 |
| US9157071B2 (en) | 2015-10-13 |
| EP2293804A1 (de) | 2011-03-16 |
| DK2700405T3 (en) | 2018-05-22 |
| ES2425489T3 (es) | 2013-10-15 |
| EP2293804B1 (de) | 2013-05-22 |
| AU2008357065B2 (en) | 2013-07-25 |
| PT2700405T (pt) | 2018-05-02 |
| PL2293804T3 (pl) | 2014-03-31 |
| JP5683455B2 (ja) | 2015-03-11 |
| PT2293804E (pt) | 2013-08-29 |
| EP2700405B1 (de) | 2018-04-04 |
| US20160074448A1 (en) | 2016-03-17 |
| HUE037311T2 (hu) | 2018-08-28 |
| DK2293804T3 (da) | 2013-08-26 |
| PL2700405T3 (pl) | 2018-08-31 |
| ES2667622T3 (es) | 2018-05-11 |